ARDEA BIOSCIENCES (RDEA) rated Buy with price target $32 by Stifel Nicolaus
ARDEA BIOSCIENCES (NASDAQ: RDEA)
rated Buy with price target $32 by Stifel Nicolaus.
Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.
research focuses on all market caps, but is a leader in small- and mid-cap research. The department is staffed predominately with industry professionals from outside Wall Street. In fact, approximately 50% of its analysts have hands-on work experience in the industry that they research. Stifel Nicolaus
believes industry experience, its opportunistic approach, and broad market cap coverage drive excess returns and its award-winning franchise.